Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

543
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
543
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.2K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exercise and nutritional prehabilitation in gastrointestinal cancer patients: prospective controlled trial assessing feasibility, safety and effects on quality of life.

BMC cancer·2026
Same author

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

American journal of hematology·2026
Same author

Performance evaluation of a CD34 expression assay by digital PCR in bone marrow harvest from healthy donors.

Transfusion·2026
Same author

Primary mediastinal B-cell lymphoma: upfront high-dose chemotherapy with autologous stem cell transplantation results in favorable long-term outcome and may spare radiotherapy.

Annals of hematology·2026
Same author

Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2026
Same author

Donor lymphocyte infusions for recurrence of myeloid neoplasms after allogeneic hematopoietic cell transplantation in the era of hypomethylating agents and BCL2 inhibitors.

Annals of hematology·2026

Related Experiment Video

Updated: Oct 7, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K

Allogeneic Stem Cell Transplantation in Multiple Myeloma.

Christine Greil1, Monika Engelhardt1, Jürgen Finke1

  • 1University Medical Center Freiburg, Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.

Cancers
|January 11, 2022
PubMed
Summary

Allogeneic stem cell transplant (allo-SCT) offers potential cure for multiple myeloma via graft-versus-myeloma effects. However, risks like graft-versus-host disease require careful consideration, especially with new immunotherapies.

Keywords:
allogeneic stem cell transplantationgraft-versus-host diseaseimmunotherapymultiple myeloma

More Related Videos

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.7K
Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.3K

Related Experiment Videos

Last Updated: Oct 7, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.7K
Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.3K

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Multiple myeloma (MM) treatment has improved, yet remains incurable, particularly for high-risk and relapsed patients.
  • Allogeneic hematopoietic stem cell transplantation (allo-SCT) offers a potential cure through graft-versus-myeloma (GvM) effects but carries significant risks.
  • Graft-versus-host disease and non-relapse mortality are key concerns associated with allo-SCT.

Purpose of the Study:

  • To review the role of allo-SCT in multiple myeloma treatment.
  • To evaluate allo-SCT in the context of novel immunomodulatory agents and combination therapies.
  • To define optimal strategies for integrating allo-SCT into myeloma management.

Main Methods:

  • Review of current literature on multiple myeloma treatment and allo-SCT.
  • Analysis of transplant-related risks versus potential benefits, including GvM effect.
  • Exploration of tandem approaches combining autologous and allogeneic SCT with reduced-intensity conditioning.

Main Results:

  • Allo-SCT can induce long-term survival and potential cure in select MM patients.
  • The GvM effect is crucial for long-term disease control post-transplant.
  • Toxicity risks must be balanced against the potential for cure, especially in high-risk patients.

Conclusions:

  • Allo-SCT should be considered for young, fit patients with high-risk multiple myeloma, particularly within clinical trials.
  • Tandem approaches using reduced-intensity conditioning post-allo-SCT may minimize toxicity while preserving the GvM effect.
  • Further research is needed to optimize allo-SCT strategies alongside new immunotherapies for multiple myeloma.